Parkinson’s Disease Relief Without Surgery

U: The Mind Company may have found a simple, non-surgical way to treat Parkinson’s disease.

The company recently shared results from its RESTORE trial (Reducing Essential and Secondary Tremor Outcomes via Rhythmic Electrical Stimulation), which treated patients with advanced Parkinson’s disease with a gentle electrical current delivered daily for 15 minutes through a scalp-worn headset.

The study was conducted at a hospital in Rawalpindi, Pakistan, and reviewed by an independent ethics board to ensure patient safety. It compared three versions of the treatment in 26 patients over 15 days. No serious side effects were reported in any patient.

In patients who responded most strongly, tremor movement dropped by up to 67%, motor function scores improved by up to 64%, and abnormal brain activity linked to tremor fell by up to 77%—all within three weeks.

Across all patients, one treatment version produced a 20.3% improvement in overall movement and quality of life, including a 54.8% improvement in non-movement symptoms like mood and sleep. A second version produced a 29.5% improvement in physical motor control. All three versions of the device performed comparably overall, suggesting the core technology rather than specific settings are driving results.

“These results were generated in three weeks. A 12-week protocol is expected to capture the full effect,” U: The Mind Company Founder/CEO Mohammed Abouelsoud said. “The companion Alzheimer’s study showed that 12 weeks produced gains that were undetectable at three weeks. We expect the same here. We are running that trial now.”

Company executives claim their technology offers a non-surgical alternative to brain implants. Other devices require surgeons to place electrodes directly inside the brain. U: The Mind Company’s device sits on the outside of the head and works through the scalp.

The device works by sending carefully designed electrical signals through the scalp toward the deep brain regions responsible for movement—the same areas damaged by Parkinson’s disease. The company’s signal patterns are protected by two granted U.S. patents, with additional patents pending.

U: The Mind Company is pursuing two tracks simultaneously: a consumer wellness device called NeuroEdge, currently available for focus and cognitive performance, and two separate medical devices targeting Parkinson’s disease (Sphere) and Alzheimer’s disease (Axis) that are up for U.S. Food and Drug Administration (FDA) approval. The company is expecting FDA clearance for Sphere and Axis in 2028.

U: The Mind Company is currently enrolling U.S. Parkinson’s patients for a remote clinical trial. The device is shipped to participants’ homes at no cost and all sessions are conducted virtually from the patient’s home. The trial is officially registered with the U.S. government at ClinicalTrials.gov (NCT07182058).

“Parkinson’s patients have been told for decades that their only options involve medication or brain surgery,” stated David Mishelevich, M.D., Ph.D., Johns Hopkins, board member and co-author of the RESTORE Trial. “These results suggest that is no longer the full picture.”

Cleveland-based U: The Mind Company is developing non-invasive brain stimulation technology for Parkinson’s disease, Alzheimer’s disease, and cognitive wellness. Founded in 2018, the company holds two granted U.S. patents with additional patents pending. Research collaborators include Mayo Clinic and MIT (Massachusetts Institute of Technology).